Requirement of Drosophila NF1 for Activation of Adenylyl Cyclase by PACAP38-Like Neuropeptides-Reference-Cited by-同舟云学术

Requirement of Drosophila NF1 for Activation of Adenylyl Cyclase by PACAP38-Like Neuropeptides

Published:1997-05-02 Issue:5313 Volume:276 Page:795-798
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Guo Hui-Fu¹²,The Inge¹²,Hannan Frances¹²,Bernards André¹²,Zhong Yi¹²

Affiliation:

1. H.-F. Guo, F. Hannan, Y. Zhong, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.

2. I. The and A. Bernards, Massachusetts General Hospital Cancer Center, Building 149, 13th Street, Charlestown, MA 02129, USA.

Abstract

The human neurofibromatosis type 1 (NF1) tumor suppressor protein functions as a Ras-specific guanosine triphosphatase–activating protein, but the identity of Ras- mediated pathways modulated by NF1 remains unknown. A study of Drosophila NF1 mutants revealed that NF1 is essential for the cellular response to the neuropeptide PACAP38 (pituitary adenylyl cyclase–activating polypeptide) at the neuromuscular junction. The peptide induced a 100-fold enhancement of potassium currents by activating the Ras-Raf and adenylyl cyclase–adenosine 3’,5’-monophosphate (cAMP) pathways. This response was eliminated in NF1 mutants. NF1 appears to regulate the rutabaga -encoded adenylyl cyclase rather than the Ras-Raf pathway. Moreover, the NF1 defect was rescued by the exposure of cells to pharmacological treatment that increased concentrations of cAMP.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference37 articles.

1. Viskochil D., White R., Cawthon R., Annu. Rev. Neurosci. 16, 183 (1993).

2. McCormick F., Curr. Opin. Genet. Dev. 5, 51 (1995);

3. North K., et al., Neurology 44, 878 (1994).

4. Xu G. F., et al., Cell 62, 599 (1990);

5. ; ibid. 63 835 (1990);

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas;Journal of Investigative Dermatology;2023-08

2. Humanization for neurological disease modeling: A roadmap to increase the potential of Drosophila model systems;Animal Models and Experimental Medicine;2023-05-08

3. A Targeted, Low-Throughput Compound Screen in aDrosophilaModel of Neurofibromatosis Type 1 Identifies Simvastatin and BMS-204352 as Potential Therapies for Autism Spectrum Disorder (ASD);eneuro;2023-04-26

4. The therapeutic potential of neurofibromin signaling pathways and binding partners;Communications Biology;2023-04-20

5. A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD);2022-11-13